Calliditas Therapeutics IPO Presentation Deck

Commercialization strategy and market opportunity in the U.S. Significant unmet medical need Commercial strategy Positioning Pricing from research Market opportunity calliditas Independent U.S. commercialization Orphan Drug 130-150k prevalence with up to 50% at risk of developing ESRD within 10-20 years www. Third party IQVIA) research commissioned by the Company Severe side effects of existing off-label treatments Disease modifying potential by delaying or avoiding progression to dialysis / transplant Earlier stage treatment to preserve kidney function and prevent progression to dialysis/ transplant Chronic / intermittent dosing ✓ Disease modifying potential- delay or avoid dialysis / transplantation Targeting of therapeutically focused nephrologists - hub-and-spoke structure Collaborate with patient / advocacy organizations Relatively small sales (~40) and marketing organization Potentially first approved on-label treatment for IgAN with disease modifying potential. Establish a new standard of care for IgAN $55,000-85,000 per patient per treatment cycle¹ Total market of $9-10bn; up to 50% at risk of developing ESRD resulting in core target market of $4.5-5bn June 2020 26

View entire presentation